 |
The Ohio bioscience sector strength was ranked #4 among USA states in 2008 by Business Facilities magazine. [2]
| |
The Ohio bioscience sector strength was ranked #4 among USA states in 2008 by Business Facilities magazine. [2]
As of 2008 [update] , there were over 1,100 biotech related firms operating in the state, [3] employing 1.4 million residents overall in direct or indirect related fields, including healthcare, with $2.5 billion in investment in 2007, making it an international leader. [4] [5] Ohio had three city-regions in the top 30 biotech locations in the country, with Cleveland-Akron ranked #20, Columbus #22, and Cincinnati #28.
The overall economic impact of the bioscience industry in Ohio, including healthcare, amounted to $148.2 billion in 2007, representing 15.7% of Ohio's economic output. [5] Half of the biotech industry is located in northeast Ohio, with 574 firms, while central and southern Ohio are home to around 200 each. [6] [7] 635 companies are FDA-certified to manufacture medical devices. [6] Biotech research and development employs directly 12,415 residents, while agricultural bioscience contributed the largest economic impact, at $10.7 billion. Medical device manufacturers employ 9,757 residents. [6]
Major firms include Meridian Bioscience in Cincinnati, which has been ranked by Fortune and Business Week as one of the top small businesses in the country; Atricure in West Chester, Ganeden Biotech in Cleveland, Cleveland Medical Devices and Orbital Research in Cleveland, [8] Stolle Milk Biologics in Cincinnati, Germany-based BASF in Whitehouse, Imalux Corporation in Cleveland, ZIN Medical in Cleveland, Theken Surgical in Akron, Ohio, Philips Medical Systems in Highland Heights, Charles River Labs in Spencerville, Freedom Meditech in Toledo, Traycer Diagnostic Systems in Columbus, Idexx Laboratories in Boardman, Ben Venue Laboratories, a division of Germany-based Boehringer Ingelheim, in Bedford, Ethicon Endo-Surgery, a subsidiary of Johnson & Johnson, located in Blue Ash, STERIS Corporation in Mentor, Chemical Abstracts Service in Columbus, Invacare in Elyria, Diagnostic Hybrids in Athens, and Synapse Biomedical in Oberlin. [6] [7]
In 2010, France-based Areva began a partnership with the University of Cincinnati to develop treatments for cancer using nuclear techniques, [9] while the Third Frontier program attracted Colorado-based Lanx Inc.'s Lumbar Motion Monitor Commercialization project, working in collaboration with the Ohio State University and Cleveland Clinic Center for Spine Health. [10]
Capital venture firms focused on biosciences include Charter Life Sciences in Cincinnati, Primus Venture Partners in Cleveland, Reservoir Venture Partners in Columbus, River Cities Capital Funds in Cincinnati, Draper Triangle Ventures in Cleveland, Ohio Innovation in Cleveland, CID Equity Partners in Columbus, Triathlon Medical Ventures in Cincinnati, and Oakwood Medical Investors in Cleveland, while JumpStart, based in Cleveland, provides funding for related ventures. [11]
Major biotech incubators include BioEnterprise in Cleveland, BIOSTART in Cincinnati, TechColumbus, and the Innovation Center in Athens. [11]
In October 2010, Austen BioInnovation Institute in Akron was cleared to begin a renovation project for their new headquarters, projected to produce 2400 new employment positions in the next decade. [12]
Biopharmaceutical companies in Ohio employ 91,750 people in Ohio, with 15,992 directly related jobs, and 75,758 indirectly related positions. [13] In 2006, wages from the sector totaled $1.2 billion, with an economic output of $14.9 billion. [13] 15.8% of clinical trials for new medicines focused on important conditions were conducted in the state in 2008, while companies invested $688 million in research and development.
Major firms include Procter & Gamble, headquartered in Cincinnati, Roxane Laboratories, a division of Boehringer Ingelheim, located in Columbus, Forest Pharmaceuticals, a subsidiary of Forest Laboratories, located in Cincinnati, Patheon in Cincinnati, Amylin Pharmaceuticals in West Chester, Auburn Pharmaceuticals in Cleveland, a Sigma-Aldrich facility in Miamisburg, Reese Pharmaceutical in Cleveland, AcelleRX Therapeutics in Cleveland, Akebia Therapeutics in Cincinnati, Kendle International in Cincinnati, Bayer in Newark, Ross Laboratories, a division of Abbott Laboratories, in Columbus, Barr Pharmaceuticals in Cincinnati, and Cardinal Health in Dublin. [6] [7] In total, there are 88 FDA-certified companies in Ohio manufacturing pharmaceuticals. [6]
In June 2010, the state's biotechnology development organization, BioOhio, announced a partnership with the Beijing Pharma and Biotech Center to develop business interests in the state and in China. [14]
Ohio is home to pharmacy chains including Revco in Twinsburg and Discount Drug Mart in Medina, and previously Phar-Mor, which was headquartered in Youngstown.
Cleveland has become recognized as a regenerative medicine research hub, due in part to the location of major research facilities in the city such as the National Center for Regenerative Medicine, Center for Stem Cell and Regenerative Medicine, Clinical Tissue Engineering Center, and the Cleveland Clinic, as well as its 30-year history of the research.
In 1986, scientists from the Case Western University filed patents related to mesenchymal stem cells, creating the foundation internationally for this sector in cellular therapeutics. The first clinical trials in the United States involving mesenchymal stem cells occurred between 1996 and 2000 at the University Hospitals of Cleveland, while the hospital was also responsible for the first adult umbilical cord transplant in 1997, and the first adult stem-cell clinical trials in the country in 2003. [15] [16]
Major regenerative medicine firms located in Cleveland include Osiris Therapeutics, started in 1994, Juventas Therapeutics, which has plans for their first clinical trial in 2010 and has raised $9.1 million in venture capital and grants, Cell Targeting Inc., which has raised $1 million in grants, [16] Invenio Therapeutics Inc., which specializes in leukemia treatments, [16] and Athersys Inc., which has developed the product Multistem, conducted 2 clinical trials, and raised $180 million in venture capital and grants. [16] Other firms include Proxy Biomedical, LucCell, Inc., and the Cleveland Cord Blood Center.
An up-and-coming firm, Arteriocyte Inc., has completed one clinical trial and raised $43 million in venture capital and grants [16] while being named as the top biotech startup in 2010 by the Ohio Venture Association. [17] The same year the company announced completion of an R&D project funded by the U.S. Department of Defense through DARPA for the development of artificial blood to be used for combat situations. [18]
Firms and institutions around the state include Center for Tissue Regeneration and Engineering at Dayton, Hi-Genomics in Toledo, BioDontos in Dublin, The Research Institute at Nationwide Children's Hospital in Columbus, SecuraCell in Canton, Stembanc, Inc. in Chardon, and Ethicord in Strongsville.
The Takeda Pharmaceutical Company Limited[takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.
F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally.
Genome Valley is an Indian high-technology business district spread across 2,000-acre (8.1 km2)/(3.1 sq mi) in Hyderabad, India. It is located across the suburbs, Turakapally, Shamirpet, Medchal, Uppal, Patancheru, Jeedimetla, Gachibowli and Keesara. The Genome Valley has developed as a cluster for Biomedical research, training and manufacturing. Genome Valley is now into its Phase III, which is about 11 kms from the Phase I and II with the total area approximately 2,000-acre (8.1 km2).
Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. On February 5, 2020, the company announced management changes effective from April 1, 2020.
The Cambridge Biomedical Campus is the largest centre of medical research and health science in Europe. The site is located at the southern end of Hills Road in Cambridge, England.
Nimotuzumab is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck, and was undergoing several clinical trials.
WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device company.
Human platelet lysate is a substitute supplement for fetal bovine serum (FBS) in experimental and clinical cell culture. It is a turbid, light-yellow liquid that is obtained from human blood platelets after freeze/thaw cycle(s). The freeze/thaw cycle causes the platelets to lyse, releasing a large quantity of growth factors necessary for cell expansion. hPL has the highest concentration of growth factors of any serum suppliments. FBS-free cell culture media, e.g. with platelet lysate or chemically defined/ animal component free, are used for cell therapy or regenerative medicine. They are commercially available in GMP -quality which is generally basis for regulatory approval.
The Center for Stem Cell and Regenerative Medicine (CSCRM) is a medical research institution specializing in stem cell and other cell therapy research and treatments, located in Cleveland, Ohio. They specialize in basic and clinical research programs, biomedical and tissue engineering programs, and the development and administration of new therapies to patients.
Ohio is a major research and development center, home to many institutions.
SynBio is a long-term project started in 2011 with the goal of creating innovative medicines, including what are known as Biobetters. This project is a collaborative effort of several Russian and international pharmaceutical companies. The largest private participant of SynBio is the Human Stem Cells Institute (HSCI), a leading Russian biotech company, and Rusnano is a key investor. The project is a significant example of international cooperation between researchers in Russia, England, and Germany. Special project company SynBio LLC is headquartered in Moscow.
BioLineRx, or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
Osiris Therapeutics, Inc. was founded in March 1993 following the identification of mesenchymal stem cells (MSCs) by Dr. Arnold Caplan and colleagues at Case Western Reserve University in Cleveland Ohio. This was years before Geron and Advanced Cell Sciences appeared and garnered massive public attention for their stem cell work. Dr. Caplan contributed a license to the technology and joined Kevin Kimberlin, James S. Burns, a biotech venture capitalist, and Peter Friedli, a "high-tech financier" and lead investor, to launch Osiris; Caplan and Burns had named the company after the Egyptian god of the "lower world". Early financing was provided by a number of entities, including Three Arch Bay Health Sciences Fund of Mountain View, California, Burns and a New York-based acquaintance of Burns. Almost immediately the company tried launching an initial public offering (IPO), but the petition was withdrawn due to low investor interest. By 1994, the state of Maryland had determined that they wanted Osiris to be based in their state, and state officials engineered a loan and equity investment which successfully lured the company from Ohio by 1995.
BioMotiv is an accelerator company associated with The Harrington Project, an initiative centered at University Hospitals of Cleveland. Therapeutic opportunities are identified through relationships with The Harrington Discovery Institute, university and research institutions, disease foundations, and industry sources. Once opportunities are identified, BioMotiv oversees the development, funding, active management, and partnering of the therapeutic products.
Gregory L. Verdine is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor. He is a founder of the field of chemical biology, which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability.
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.
David L. Lucchino is co-founder and chief executive officer of Frequency Therapeutics, a biotechnology company based in Lexington, MA.
Hans Keirstead is a medical scientist and entrepreneur specializing in stem cell research.
BIOTECanada, or the Industrial Biotechnology Association of Canada, is a Canadian biotechnology industry association based in Ottawa, Ontario. It is an industry-funded membership organization composed of over 250 national and international pharmaceutical and gene therapy companies, medical device manufacturers, agricultural science businesses, law firms, academic institutions, research and development networks, advertising agencies, insurance companies and financial services firms.